Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Sep 30, 2026, 8:33 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 41 matching trials from the live ClinicalTrials.gov search.
Filters: Intervention: Placebo (for Tamoxifen) Clear all
Active, not recruiting Phase 3 Interventional Results available

S1207 Hormone Therapy With or Without Everolimus in Treating Patients With Breast Cancer

NCT01674140
View directory record Official record
Conditions
Breast Cancer
Interventions
anastrozole, everolimus, exemestane, goserelin acetate, letrozole, leuprolide acetate, tamoxifen citrate, placebo
Drug · Other
Lead sponsor
SWOG Cancer Research Network
Network
Eligibility
18 Years and older
Enrollment
1,939 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2030
U.S. locations
1455
States / cities
Birmingham, Alabama • Anchorage, Alaska • Fairbanks, Alaska + 887 more
Source: ClinicalTrials.gov public record
Updated Feb 10, 2026 · Synced Sep 30, 2026, 8:33 AM EDT
Completed Phase 3 Interventional

Toremifene Citrate for Prevention of Bone Fractures in Men With Prostate Cancer on Androgen Deprivation Therapy

NCT00129142
View directory record Official record
Conditions
Prostate Cancer, Osteoporosis, Fractures
Interventions
Toremifene Citrate
Drug
Lead sponsor
GTx
Industry
Eligibility
50 Years and older · Male only
Enrollment
1,200 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2003 – 2007
U.S. locations
136
States / cities
Homewood, Alabama • Mobile, Alabama • Little Rock, Arkansas + 117 more
Source: ClinicalTrials.gov public record
Updated Nov 15, 2013 · Synced Sep 30, 2026, 8:33 AM EDT
Completed Phase 2 Interventional Results available

Testing an Active Form of Tamoxifen (4-hydroxytamoxifen) Delivered Through Breast Skin to Control Ductal Carcinoma in Situ (DCIS) of the Breast

NCT02993159
View directory record Official record
Conditions
Ductal Breast Carcinoma In Situ, Estrogen Receptor Positive
Interventions
Afimoxifene, Laboratory Biomarker Analysis, Placebo, Tamoxifen Citrate
Drug · Other
Lead sponsor
Northwestern University
Other
Eligibility
18 Years and older · Female only
Enrollment
100 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2022
U.S. locations
6
States / cities
Chicago, Illinois • Edgewood, Kentucky • Rochester, Minnesota + 3 more
Source: ClinicalTrials.gov public record
Updated Dec 18, 2024 · Synced Sep 30, 2026, 8:33 AM EDT
Completed Phase 2 Interventional Results available

Tamoxifen Therapy to Treat Pulmonary Arterial Hypertension

NCT03528902
View directory record Official record
Conditions
Hypertension, Pulmonary Arterial Hypertension, Familial Primary Pulmonary Hypertension, Primary Pulmonary Hypertension, Lung Diseases, Tamoxifen, Estrogen Receptor Antagonist, Hormone Antagonists, Estrogens
Interventions
Tamoxifen, Placebo Oral Tablet
Drug
Lead sponsor
Vanderbilt University Medical Center
Other
Eligibility
18 Years and older
Enrollment
18 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2023
U.S. locations
1
States / cities
Nashville, Tennessee
Source: ClinicalTrials.gov public record
Updated Dec 5, 2024 · Synced Sep 30, 2026, 8:33 AM EDT
Completed Phase 2 Interventional

Chemoprevention Therapy Plus Surgery in Treating Women With Breast Cancer

NCT00003099
View directory record Official record
Conditions
Breast Cancer
Interventions
Fenretinide, Tamoxifen Citrate, Placebo
Drug · Other
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
18 Years and older · Female only
Enrollment
52 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
1996 – 2003
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Jul 30, 2012 · Synced Sep 30, 2026, 8:33 AM EDT
Completed Phase 3 Interventional

Raloxifene Use for The Heart

NCT00190593
View directory record Official record
Conditions
Cardiovascular Diseases, Breast Neoplasms
Interventions
raloxifene, placebo
Drug
Lead sponsor
Eli Lilly and Company
Industry
Eligibility
55 Years and older · Female only
Enrollment
10,000 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
1998 – 2005
U.S. locations
1
States / cities
Minneapolis, Minnesota
Source: ClinicalTrials.gov public record
Updated Jan 26, 2007 · Synced Sep 30, 2026, 8:33 AM EDT
Completed Phase 2 Interventional Results available

Safety and Efficacy Study of Creatine and Tamoxifen in Volunteers With Amyotrophic Lateral Sclerosis (ALS)

NCT01257581
View directory record Official record
Conditions
Amyotrophic Lateral Sclerosis
Interventions
creatine, tamoxifen
Drug
Lead sponsor
Nazem Atassi
Other
Eligibility
18 Years and older
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2013
U.S. locations
9
States / cities
Kansas City, Kansas • Boston, Massachusetts • Worcester, Massachusetts + 6 more
Source: ClinicalTrials.gov public record
Updated Dec 4, 2014 · Synced Sep 30, 2026, 8:33 AM EDT
Recruiting Phase 2 Interventional

New Treatment Strategies and Epigenetic Biomarker for Management of Benign Prostatic Hyperplasia

NCT06944145
View directory record Official record
Conditions
BPH (Benign Prostatic Hyperplasia), Lower Urinary Track Symptoms
Interventions
raloxifene, Finasteride
Drug
Lead sponsor
Beth Israel Deaconess Medical Center
Other
Eligibility
18 Years and older · Male only
Enrollment
242 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2030
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Mar 23, 2026 · Synced Sep 30, 2026, 8:33 AM EDT
Terminated Phase 4 Interventional

Risedronate vs Raloxifene in Hormone Replacement Therapy Discontinuation

NCT00790101
View directory record Official record
Conditions
Osteoporosis, Postmenopausal
Interventions
Risedronate, Raloxifene, Placebo
Drug · Other
Lead sponsor
Sanofi
Industry
Eligibility
Up to 65 Years · Female only
Enrollment
6 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004
U.S. locations
1
States / cities
Bridgewater, New Jersey
Source: ClinicalTrials.gov public record
Updated Jan 11, 2011 · Synced Sep 30, 2026, 8:33 AM EDT
Terminated No phase listed Observational

Observational Study Analyzing RNA Expression Of Endometrial Biopsy Samples From Placebo, Bazedoxifene/Conjugated Estrogens And Raloxifene

NCT00847821
View directory record Official record
Conditions
Postmenopause
Interventions
Bazedoxifene 10 mg/CE 0.625 mg, Bazedoxifene 20 mg/CE 0.625 mg, Bazedoxifene 40 mg/CE 0.625 mg, Bazedoxifene 10 mg/CE 0.45 mg, Bazedoxifene 20 mg/CE 0.45 mg, Bazedoxifene 40 mg/CE 0.45 mg, Raloxifene 60 mg, Placebo
Drug
Lead sponsor
Wyeth is now a wholly owned subsidiary of Pfizer
Industry
Eligibility
40 Years to 75 Years · Female only
Enrollment
185 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2010
U.S. locations
22
States / cities
Fort Myers, Florida • Gainesville, Florida • New Port Richey, Florida + 19 more
Source: ClinicalTrials.gov public record
Updated Sep 6, 2010 · Synced Sep 30, 2026, 8:33 AM EDT
Terminated Phase 1Phase 2 Interventional

Tamoxifen Therapy for Myotubular Myopathy

NCT04915846
View directory record Official record
Conditions
X Linked Myotubular Myopathy
Interventions
ApoTamox 10mg, Placebo
Drug
Lead sponsor
James Dowling
Other
Eligibility
6 Months and older · Male only
Enrollment
6 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2024
U.S. locations
2
States / cities
Chicago, Illinois • Rockville, Maryland
Source: ClinicalTrials.gov public record
Updated Sep 19, 2024 · Synced Sep 30, 2026, 8:33 AM EDT
Active, not recruiting Phase 2 Interventional Results available

Low-Dose Tamoxifen Citrate in Reducing Breast Cancer Risk in Radiation-Induced Cancer Survivors

NCT01196936
View directory record Official record
Conditions
Breast Cancer
Interventions
Tamoxifen Citrate, Placebo, Digital mammography, immunohistochemistry staining method, pharmacological study, laboratory biomarker analysis, protein expression analysis, pharmacogenomic studies, questionnaire administration, Fine needle aspiration, Quality of Life Assessment
Drug · Procedure · Other + 1 more
Lead sponsor
University of Alabama at Birmingham
Other
Eligibility
25 Years and older · Female only
Enrollment
84 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2028
U.S. locations
12
States / cities
Birmingham, Alabama • Duarte, California • Aurora, Colorado + 9 more
Source: ClinicalTrials.gov public record
Updated Jan 5, 2026 · Synced Sep 30, 2026, 8:33 AM EDT
Completed Phase 3 Interventional

Exemestane in Treating Postmenopausal Women With Resected Stage I, Stage II, or Stage IIIA Breast Cancer Who Have Completed 5 Years of Tamoxifen

NCT00016432
View directory record Official record
Conditions
Breast Cancer
Interventions
exemestane, Placebo
Drug
Lead sponsor
NSABP Foundation Inc
Network
Eligibility
18 Years and older · Female only
Enrollment
1,598 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2001 – 2011
U.S. locations
150
States / cities
Huntsville, Alabama • Phoenix, Arizona • Little Rock, Arkansas + 129 more
Source: ClinicalTrials.gov public record
Updated Apr 19, 2011 · Synced Sep 30, 2026, 8:33 AM EDT
Completed Phase 2 Interventional Results available

Adjuvant Ribociclib With Endocrine Therapy in Hormone Receptor+/HER2- High Risk Early Breast Cancer

NCT03078751
View directory record Official record
Conditions
Breast Cancer
Interventions
Ribociclib, Adjuvant endocrine therapy, Placebo
Drug
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
18 Years and older
Enrollment
54 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2020
U.S. locations
33
States / cities
Tucson, Arizona • Fayetteville, Arkansas • Bakersfield, California + 28 more
Source: ClinicalTrials.gov public record
Updated Oct 11, 2021 · Synced Sep 30, 2026, 8:33 AM EDT
Completed Phase 2 Interventional Accepts healthy volunteers Results available

Afimoxifene in Reducing the Risk of Breast Cancer in Women With Mammographically Dense Breast

NCT03063619
View directory record Official record
Conditions
Mammographically Dense Breast
Interventions
Afimoxifene, Laboratory Biomarker Analysis, Placebo, Questionnaire Administration
Drug · Other
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
40 Years to 69 Years · Female only
Enrollment
194 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2018 – 2021
U.S. locations
5
States / cities
Tampa, Florida • Chicago, Illinois • Boston, Massachusetts + 2 more
Source: ClinicalTrials.gov public record
Updated Feb 22, 2024 · Synced Sep 30, 2026, 8:33 AM EDT
Terminated Phase 3 Interventional Results available

Trial of 4-Hydroxytamoxifen (4-OHT) Gel in Women Aimed at Reducing Dense Breast Tissue

NCT03199963
View directory record Official record
Conditions
Mammographic Breast Density
Interventions
4-OH tamoxifen, Placebo
Drug
Lead sponsor
BHR Pharma, LLC
Industry
Eligibility
35 Years to 75 Years · Female only
Enrollment
223 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2019
U.S. locations
17
States / cities
Mesa, Arizona • Tucson, Arizona • Beverly Hills, California + 14 more
Source: ClinicalTrials.gov public record
Updated Jul 26, 2022 · Synced Sep 30, 2026, 8:33 AM EDT
Completed Phase 4 Interventional Accepts healthy volunteers Results available

Tamoxifen to Reduce Unscheduled Bleeding in New Users of the Levonorgestrel-releasing Intrauterine System (LNG-IUS)

NCT02824224
View directory record Official record
Conditions
Menorrhagia, Metrorrhagia, Medicated Intrauterine Devices
Interventions
Tamoxifen, Placebo (for Tamoxifen)
Drug
Lead sponsor
Oregon Health and Science University
Other
Eligibility
15 Years to 45 Years · Female only
Enrollment
42 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2016 – 2018
U.S. locations
1
States / cities
Portland, Oregon
Source: ClinicalTrials.gov public record
Updated Jun 4, 2019 · Synced Sep 30, 2026, 8:33 AM EDT
Completed Not applicable Interventional

Diindolylmethane in Treating Patients With Breast Cancer

NCT01391689
View directory record Official record
Conditions
Stage IA Breast Cancer, Stage IB Breast Cancer, Stage II Breast Cancer, Stage IIIA Breast Cancer
Interventions
diindolylmethane, placebo
Dietary Supplement
Lead sponsor
University of Arizona
Other
Eligibility
19 Years and older · Female only
Enrollment
144 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2016
U.S. locations
1
States / cities
Tucson, Arizona
Source: ClinicalTrials.gov public record
Updated Nov 6, 2017 · Synced Sep 30, 2026, 8:33 AM EDT
Completed Phase 2 Interventional Results available

Raloxifene for Women With Alzheimer's Disease

NCT00368459
View directory record Official record
Conditions
Alzheimer Disease
Interventions
raloxifene, Placebo
Drug
Lead sponsor
Stanford University
Other
Eligibility
60 Years and older · Female only
Enrollment
42 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2012
U.S. locations
4
States / cities
Santa Rosa, California • Stanford, California • Springfield, Illinois + 1 more
Source: ClinicalTrials.gov public record
Updated Apr 2, 2015 · Synced Sep 30, 2026, 8:33 AM EDT
Terminated Phase 2 Interventional

Tamoxifen in Preventing Breast Cancer in Women at Increased Risk for Breast Cancer

NCT00096369
View directory record Official record
Conditions
Breast Cancer
Interventions
tamoxifen citrate
Drug
Lead sponsor
University of Texas Southwestern Medical Center
Other
Eligibility
35 Years to 120 Years · Female only
Enrollment
130 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2000 – 2007
U.S. locations
4
States / cities
Oklahoma City, Oklahoma • Dallas, Texas • Houston, Texas + 1 more
Source: ClinicalTrials.gov public record
Updated Jan 24, 2019 · Synced Sep 30, 2026, 8:33 AM EDT
Completed Phase 3 Interventional Accepts healthy volunteers

Comparison of Raloxifene and Lasofoxifene - A Randomized, Blinded Study of These Drugs and Placebo on Bone Loss

NCT00163137
View directory record Official record
Conditions
Osteoporosis
Interventions
lasofoxifene, raloxifene, Placebo
Drug
Lead sponsor
Ligand Pharmaceuticals
Industry
Eligibility
48 Years to 75 Years · Female only
Enrollment
540 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2003 – 2005
U.S. locations
72
States / cities
Albany, California • Berkeley, California • La Jolla, California + 49 more
Source: ClinicalTrials.gov public record
Updated Aug 12, 2011 · Synced Sep 30, 2026, 8:33 AM EDT
Not listed No phase listed Observational Accepts healthy volunteers

Efficacy Of Tocotrienol a Natural Vitamin E In Biopsy Wound

NCT01579227
View directory record Official record
Conditions
Scar
Interventions
Topical Tocotrienol (TCT), Oral Tocotrienol Capsules (TCT), Tamoxifen Cream, Placebo cream, placebo capsule
Device · Dietary Supplement
Lead sponsor
Chandan K Sen
Other
Eligibility
18 Years to 50 Years
Enrollment
101 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2012 – 2018
U.S. locations
1
States / cities
Columbus, Ohio
Source: ClinicalTrials.gov public record
Updated Jan 29, 2018 · Synced Sep 30, 2026, 8:33 AM EDT
Withdrawn Phase 3 Interventional

Efficacy and Safety Study of Toremifene Citrate for the Reduction in the Risk of New Bone Fracture Occurrences in Men With Prostate Cancer

NCT01214291
View directory record Official record
Conditions
Risk of Bone Fracture Occurrences
Interventions
Toremifene
Drug
Lead sponsor
GTx
Industry
Eligibility
50 Years to 80 Years · Male only
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011
U.S. locations
1
States / cities
Seattle, Washington
Source: ClinicalTrials.gov public record
Updated Nov 15, 2013 · Synced Sep 30, 2026, 8:33 AM EDT
Completed Phase 3 Interventional Results available

Prostate Cancer Prevention Study for Men With High Grade PIN (Prostatic Intraepithelial Neoplasia)

NCT00106691
View directory record Official record
Conditions
Preneoplastic Conditions, Prostatic Intraepithelial Neoplasia
Interventions
Toremifene 20 mg, Placebo
Drug
Lead sponsor
GTx
Industry
Eligibility
30 Years and older · Male only
Enrollment
1,589 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2010
U.S. locations
108
States / cities
Huntsville, Alabama • Mobile, Alabama • Phoenix, Arizona + 93 more
Source: ClinicalTrials.gov public record
Updated Jun 12, 2023 · Synced Sep 30, 2026, 8:33 AM EDT